Trends in diabetes: sounding the alarm  by Krug, Etienne G
Comment
www.thelancet.com   Vol 387   April 9, 2016 1485
Trends in diabetes: sounding the alarm
Diabetes is a major cause of death and disability 
worldwide. In 2012 it caused as many deaths as HIV/AIDS 
(1·5 million).1 Disability resulting from diabetes has grown 
substantially since 1990, with particularly large increases 
among people aged 15–69 years.2 People with all types of 
diabetes are at risk of developing a range of complications 
that can endanger their health and survival, and the high 
costs of care increase the risk of catastrophic medical 
expenditure.3 Diabetes is the theme of this year’s World 
Health Day on April 7, and WHO has published the 
Global Report on Diabetes to raise awareness and spark 
momentum for action at the necessary scale.
In The Lancet, the NCD Risk Factor Collab-
oration (NCD-RisC)4 presents a robust and timely 
analysis of trends in diabetes prevalence. They provide 
updated, consistent, and comparable estimates of age-
standardised prevalence of diabetes since 1980, derived 
from 751 population-based measurement studies 
involving nearly 4·4 million participants. These are 
the ﬁ rst global estimates and trend analyses published 
since adoption of the voluntary target to halt the rise in 
diabetes and obesity (against the 2010 baseline) by 2025.
The news is not good. NCD-RisC estimates that the 
number of people with diabetes quadrupled between 
1980 and 2014. Age-standardised prevalence among 
adult men doubled during that time (from 4·3% 
[95% credible interval 2·4–7·0] to 9·0% [7·2–11·1]), 
and age-standardised prevalence among adult women 
increased by 60% (5·0% [2·9–7·9] to 7·9% [6·4–9·7]). 
Diabetes prevalence either increased or remained the 
same in every country. Given these trends, the authors 
calculate that only a few countries, mostly in western 
Europe, have even a chance of meeting the target to 
halt the rise in diabetes by 2025—a sobering wake-up 
call. With diabetes in the World Health Day spotlight the 
question is, how will the world and its leaders respond to 
the alarm?
NCD-RisC notes that reducing the global health and 
economic impact of diabetes requires action to prevent or 
delay the onset of type 2 diabetes, which accounts for the 
majority of diabetes worldwide. Overweight and obesity, 
together with physical inactivity, are responsible for a 
substantial proportion of the global diabetes burden.5 
Changes at population level to improve access to healthy 
foods and beverages, and to opportunities for physical 
activity, facilitate positive behaviour change and are likely 
to have an impact on the occurrence of type 2 diabetes.6
 The intermediate approach proposed by the 
authors—supportive intervention to promote changes 
in diet and physical activity among people at high 
risk of type 2 diabetes, possibly accompanied by the 
use of medications—is backed by strong evidence of 
eﬀ ectiveness.7–11 The ultimate advisability of targeted 
interventions for people at high risk depends heavily on 
local context, such as availability of suﬃ  cient human and 
ﬁ nancial resources, as well as essential equipment and 
technology, to manage the approach at the primary-care 
level.
Hundreds of millions of people live with diabetes today. 
Many of them do not know it, and many of those who 
do lack access to the necessary medicines or information. 
Action to build the capacity of health systems to improve 
diabetes management and reduce complications is 
a matter of urgency. Access to eﬀ ective treatment 
must be expanded through the use of standardised 
protocols and the implementation of measures to 
improve the availability of essential technologies for 
diagnosis and management of diabetes (such as blood 
glucose measurement) in primary health-care settings, 
and essential medicines such as life-saving insulin.12 
Diabetes management should be part of overall non-
communicable disease management and incorporated 
into the package of essential services included in universal 
health coverage.
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For more on the Global Report on 
Diabetes see http://www.who.
int/diabetes/global-report
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Zika virus was ﬁ rst identiﬁ ed in Africa in 1947, where 
it continues to cause regular outbreaks in sub-Saharan 
Africa but with very few clinical cases. In 1966, a 
distinct Asian lineage was found in Malaysia,1 but 
human disease remained uncommon in the Asia-
Paciﬁ c region, despite serological surveys suggesting 
widespread occurrence of subclinical infections. The 
ﬁ rst recognised epidemic happened on the Micronesian 
island of Yap in 2007. It then spread across the Paciﬁ c 
to Easter Island and in 2015–16, it emerged in South 
and Central America and the Caribbean.2 The virus is 
maintained primarily in a cycle between humans and 
Aedes aegypti mosquitoes.
The symptomatic illness is nearly always a mild, 
self-limiting illness with fever, rash, joint pain, and 
conjunctivitis. Normally this would not have attracted 
the attention of the world in the way that Zika has. 
Reports linking Zika with microcephaly and fetal deaths 
in the Americas, and with serious neurological disease, 
particularly Guillain-Barré syndrome, have led to the 
WHO declaring the outbreak a global emergency.3 In 
The Lancet, Van-Mai Cao-Lormeau and colleagues4 
present the ﬁ rst strong evidence that Zika virus can 
cause Guillain-Barré syndrome.
Guillain-Barré syndrome is a serious immune-
mediated illness manifesting as progressive paralysis 
over 1–3 weeks, with a 5% death rate and up to 20% 
of patients left with a signiﬁ cant disability.5 Several 
other ﬂ aviviruses have been found to be rare triggers 
of Guillain-Barré syndrome, including Japanese 
encephalitis virus, West Nile virus, dengue viruses,6 and 
the live-attenuated yellow fever vaccine. So it should 
not have been a surprise when a tentative Zika-induced 
case of Guillain-Barré syndrome was reported from 
French Polynesia in 2013.7
This new case-control study4 is based on 42 notiﬁ ed 
cases of Guillain-Barré syndrome in French Polynesia 
during their 2013–14 Zika epidemic. Unfortunately, 
the patients were no longer viraemic at the time of 
presentation and urine samples, which remain PCR 
positive for longer,8 were not available for testing. So 
the authors faced major challenges in proving recent 
Zika virus and Guillain-Barré syndrome: another viral cause 
to add to the list
The prevalence estimates provided by NCD-RisC sound 
the alarm for large-scale, eﬀ ective action to reduce the 
health and economic impact of diabetes. Improvements 
in prevention and management, together with better 
surveillance, should be prioritised in response to this call.
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